Topics:
Radiation Oncology • Thoracic Malignancies • Medical Oncology • Thoracic Surgery • Non-small cell lung cancer
For oligometastatic NSCLC that would be otherwise considered stage 3, would you consider consolidative immunotherapy with durvalumab after definitive treatment for both the primary and oligometastatic site?
Answer from: Medical Oncologist at Academic Institution
The occurrence of NSCLC defined by “stage III†disease in the chest, i.e. a primary lesion and mediastinal nodal involvement with an accompanying solitary metastasis elsewhere in the body (most typically another lobe of the lung, adrenal or brain) is a situation t...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
This is an excellent question and timely in light of the greater numbers of patients being referred for "definitive treatment" of limited metastatic NSCLC. I fully agree with @Martin J. Edelman that there are multiple reasons/justification to offer these patients IO after their "definitive ther...